Q/C Technologies, Inc. (QCLS)
Nasdaq: QCLS · In Vitro & In Vivo Diagnostic Substances · New York, NY · filing with the SEC since 2005
Who owns Q/C Technologies, Inc.
As filed with the SECHolders of 5% or more
1
PharmaCyte Biotech, Inc. holds 74% of Common Stock, par value $0.001 per share, as its SCHEDULE 13D/A filed Nov 18, 2025 says.
Directors and officers
9
report now, of 24 people on the record since 2014. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
PharmaCyte Biotech, Inc.
SCHEDULE 13D/A · filed Nov 18, 2025 · Common Stock, par value $0.001 per share
What QCLS reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
LPU Holdings LLC
An investee · investee · invested in, named in the 10-K filed Apr 15, 2026
3 subsidiaries in 1 country, from the list filed with the 10-K filed Apr 15, 2026.
Insider tradesForm 4
0sales
1purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 2, 2025 to Oct 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window1 of 28 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Voss Chelsea Sierra | director | 0 | $0 | 0 | 1 | $0 |